shutterstock_1569359980_sundry_photography
Sundry Photography / Shutterstock.com
18 November 2021AmericasMuireann Bolger

Gilead ruling ‘threatens life-saving research’, says St Judes

The US Court of Appeals for the Federal Circuit should revisit a ruling in favour of Gilead Sciences that invalidated a cancer drug patent because the decision jeopardises research, according to St Judes Children’s Research Hospital.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
16 February 2021   Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.
Medtech
12 April 2022   Abbot-owned St Jude Medical will have to defend claims that its catheters infringe a company’s revived patent.
Americas
10 January 2023   Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.

More on this story

Big Pharma
16 February 2021   Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.
Medtech
12 April 2022   Abbot-owned St Jude Medical will have to defend claims that its catheters infringe a company’s revived patent.
Americas
10 January 2023   Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.

More on this story

Big Pharma
16 February 2021   Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.
Medtech
12 April 2022   Abbot-owned St Jude Medical will have to defend claims that its catheters infringe a company’s revived patent.
Americas
10 January 2023   Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.